| Similar Articles |
|---|
 |
The Motley Fool
March 14, 2008
Brian Orelli |
No Slowdown for China's WuXi Chinese drug researcher and manufacturer WuXi signs more drug development deals and buys a U.S. manufacturing services company.   |
The Motley Fool
August 13, 2009
Brian Orelli |
WuXi: Making Money Both Ways Cost-cutting and revenue growth make pharma outsourcing specialist WuXi a looker for the year. |
The Motley Fool
November 12, 2009
Brian Orelli |
How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way. |
The Motley Fool
October 1, 2008
Brian Orelli |
WuXi and Covance Call It Quits WuXi PharmaTech and Covance broke up yesterday - just three months after announcing they'd form an alliance to perform pre-clinical research for drug developers looking for research and development on the cheap. |
The Motley Fool
June 25, 2008
Brian Orelli |
WuXi's Shortsighted Deal WuXi partners with Covance, but is it really a good long-term play? |
The Motley Fool
December 27, 2007
Brian Orelli |
Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there. |
The Motley Fool
August 13, 2007
Andrew R. Vaino |
Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow. |
The Motley Fool
August 1, 2008
Brian Orelli |
Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit. |
The Motley Fool
April 27, 2010
Brian Orelli |
Big Acquisition, Double-Digit Decline. Charles River Labs buys into China big time. But investors would rather have seen it stay home. |
The Motley Fool
March 6, 2009
Brian Orelli |
For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations. |
The Motley Fool
December 28, 2007
Brian Orelli |
The Biggest Health-Care IPOs of 2007 Let's take a look at four of the most intriguing health care IPOs from 2007. |
The Motley Fool
May 13, 2008
Brian Orelli |
Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company. |
The Motley Fool
October 11, 2007
Billy Fisher |
An IPO That Hit the Bull's-Eye Sirtris Pharmaceuticals presents promising drug data and is turning out to be one of the top-performing IPOs in the biotech/pharmaceutical field in 2007. |
Pharmaceutical Executive
September 1, 2008
Zhu Shen |
Unleash the Dragon Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital. |
The Motley Fool
June 28, 2010
Tim Hanson |
Will China Make Us Rich? Portfolio diversification works for a reason. |
